Neurocrine Biosciences Inc (NBIX)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	233,000	349,100	139,700	396,300	251,100	293,700	160,200	103,800	262,900	212,200	163,300	270,200	340,800	311,100	368,000	352,600	187,100	425,300	415,100	187,000
Short-term investments	US$ in thousands	843,100	878,900	899,200	814,300	780,500	801,400	816,500	790,800	726,400	587,200	485,000	394,700	370,500	454,800	516,900	521,100	613,900	519,400	533,200	584,700
Total current liabilities	US$ in thousands	507,700	429,700	398,500	712,900	654,800	691,600	582,500	374,100	537,700	485,100	285,700	253,500	245,800	225,900	212,900	190,000	186,500	611,000	573,000	140,300
Cash ratio		2.12	2.86	2.61	1.70	1.58	1.58	1.68	2.39	1.84	1.65	2.27	2.62	2.89	3.39	4.16	4.60	4.29	1.55	1.65	5.50

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($233,000K + $843,100K) ÷ $507,700K
= 2.12

The cash ratio of Neurocrine Biosciences Inc has shown fluctuation over the past few years. It started at a high of 5.50 on March 31, 2020, indicating a strong ability to cover short-term liabilities with cash. However, the ratio declined in the subsequent quarters, reaching a low of 1.55 on September 30, 2020.

The cash ratio then started to improve gradually, reaching 4.60 by March 31, 2021, showing a better liquidity position. The ratio hovered above 4 for a few quarters before starting to decline again.

As of December 31, 2024, the cash ratio stands at 2.12, indicating that Neurocrine Biosciences Inc has a moderate ability to cover short-term liabilities with its available cash. It is important for the company to monitor and manage its cash position to ensure it can meet its financial obligations in the future.